Study reports two-year outcomes of diabetic macular edema treatment

A randomized controlled trial involving patients with persistent clinically significant diabetic macular edema (swelling of the retina) suggests the greater efficacy of bevacizumab compared with macular laser therapy that was previously demonstrated at 12 months was maintained through 24 months, according to a report published Online First by Archives of Ophthalmology.

Modified Early Treatment Diabetic Retinopathy Study (ETDRS) macular (MLT) has been the mainstay of treatment for clinically significant diabetic macular edema (CSME) for the . The procedure reduces the risk of moderate visual loss but visual acuity improves (a 15-letter gain at three years) in less than 3 percent of patients so better treatments have been sought, the authors write in their study background.

Ranjan Rajendram, M.D., F.R.C.Ophth., of Moorfields Eye Hospital, London, and colleagues report on the two-year outcomes of the BOLT study, a prospective of 80 patients that evaluated intravitreous (injections into the eye) and modified ETDRS MLT in patients with CSME.

At two years, the mean (average) ETDRS best-corrected visual acuity was 64.4 (Snellen visual acuity equivalent: 20/50) in the bevacizumab group and 54.8 (Snellen equivalent 20/80) in the MLT group, a mean gain of 8.6 letters for bevacizumab and a mean loss of 0.5 letters for MLT. The bevacizumab group gained a median of nine ETDRS letters versus 2.5 ETDRS letters for MLT at 24 months compared with baseline. At 24 months, 49 percent of patients gained 10 or more ETDRS letters and 32 percent gained 15 or more letters in the bevacizumab group compared with 7 percent and 4 percent in the MLT group.

"In conclusion, this investigator-initiated single-center study provides evidence for the longer-term use of bevacizumab in the treatment of persistent DME [diabetic macular edema]," the authors note " benefit was maintained through two years with a reduced injection frequency in the second year despite the long duration of DME and multiple MLTs before entering the study. This finding will be reassuring to physicians charged with delivery of this relatively new treatment."

More information: Arch Ophthalmol. Published online April 9, 2012. doi:10.1001/archophthalmol.2012.393

Related Stories

Recommended for you

Carnival game mimics eye growth

date 4 hours ago

The motion of coins in a "Penny Pusher" carnival game is similar to the movement of cells in the eye's lens, as described in a new study published in Investigative Ophthalmology & Visual Science (IOVS). This new insight m ...

Minimal device maximizes macula imaging

date Mar 18, 2015

A smart and simple method developed at Rice University to image a patient's eye could help monitor eye health and spot signs of macular degeneration and diabetic retinopathy, especially in developing nations.

As glaucoma cases soar, researchers focus on solutions

date Mar 12, 2015

Ernest Murry saw glaucoma steal his mother's vision, just as it had robbed sight from many other family members. There was a time when it seemed the same might happen to him. "When I went outside to walk, ...

Wound leak critical complication post open globe repair

date Mar 04, 2015

(HealthDay)—Postoperative wound leak affects a substantial proportion of eyes following repair of open globe injuries, according to a study published online Feb. 17 in Clinical & Experimental Ophthalmology.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.